利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

83 条记录 (耗时 0.032 秒)

    Nanoparticulate and Controlled Release Compositions Comprising a Cephalosporin
    2.
    发明申请
    Nanoparticulate and Controlled Release Compositions Comprising a Cephalosporin 审中-公开
    包含头孢菌素的纳米颗粒和控释组合物

    公开(公告)号：US20090269400A1

    公开(公告)日：2009-10-29

    申请号：US11568825

    申请日：2006-05-16

    申请人： John Devane ,  Paul Stark ,  Niall Fanning ,  Gurvinder Rekhi ,  Scott Jenkins ,  Gary Liversidge

    发明人： John Devane ,  Paul Stark ,  Niall Fanning ,  Gurvinder Rekhi ,  Scott Jenkins ,  Gary Liversidge

    IPC分类号： A61K9/48 ,  A61K9/20 ,  A61K9/10 ,  A61K9/14 ,  A61K9/50 ,  A61P19/10 ,  A61K31/545 ,  A61K31/546

    CPC分类号： A61K9/14 ,  A61K9/1676 ,  A61K9/5078

    摘要： The present invention is directed to compositions comprising a nanoparticulate antibiotic having improved bioavailability. Preferably, the antibiotic comprises nanoparticulate cephalosporin particles with an effective average particle size of less than about 2000 nm and are useful in the treatment of bacterial infection. The invention also relates to a controlled release composition comprising a cephalosporin or a nanoparticulate cephalosporin that in operation delivers the drug in a pulsed or bimodal manner for the treatment of bacterial infection. The nanoparticulate cephalosporin particles may be formulated as a controlled release drug delivery system whereby the particles are coated one or more times with one or more natural or synthetic hydrophilic or hydrophobic polymer coating materials or dispersed throughout a natural or synthetic hydrophilic and/or hydrophobic polymer matrix.

    摘要翻译： 本发明涉及包含具有改善的生物利用度的纳米颗粒抗生素的组合物。 优选地，抗生素包含有效平均粒度小于约2000nm的纳米微粒头孢菌素颗粒，并且可用于治疗细菌感染。 本发明还涉及包含头孢菌素或纳米微粒头孢菌素的控释组合物，其在操作中以脉冲或双峰方式递送药物用于治疗细菌感染。 纳米颗粒头孢菌素颗粒可以配制成控释药物递送系统，由此颗粒用一种或多种天然或合成的亲水或疏水性聚合物涂层材料涂覆一次或多次，或分散在整个天然或合成的亲水和/或疏水性聚合物基质中 。

    Multiparticulate modified release composition
    4.
    发明申请
    Multiparticulate modified release composition 审中-公开
    多微粒改性组合物

    公开(公告)号：US20060240105A1

    公开(公告)日：2006-10-26

    申请号：US11372857

    申请日：2006-03-10

    申请人： John Devane ,  Paul Stark ,  Niall Fanning ,  Gurvinder Rekhi ,  Scott Jenkins ,  Gary Liversidge

    发明人： John Devane ,  Paul Stark ,  Niall Fanning ,  Gurvinder Rekhi ,  Scott Jenkins ,  Gary Liversidge

    IPC分类号： A61K31/485 ,  A61K31/192 ,  A61K9/26

    CPC分类号： A61K31/485 ,  A61K9/501 ,  A61K9/5015 ,  A61K9/5026 ,  A61K9/5047 ,  A61K9/5084 ,  A61K31/192

    摘要： The invention relates to a multiparticulate modified release composition that, upon administration to a patient, delivers at least one active ingredient in a bimodal or multimodal manner. The multiparticulate modified release composition comprises a first component and at least one subsequent component; the first component comprising a first population of active ingredient containing particles and the at least one subsequent component comprising a second population of active ingredient containing particles wherein the combination of the components exhibit a bimodal or multimodal release profile. The invention also relates to a solid oral dosage form containing such a multiparticulate modified release composition.

    摘要翻译： 本发明涉及一种多微粒改性释放组合物，其在给予患者时以双峰或多峰方式递送至少一种活性成分。 多微粒改性组合物包含第一组分和至少一个后续组分; 所述第一组分包含含有颗粒的第一组活性成分和所述至少一种随后组分，所述至少一种后续组分包含含有颗粒的第二组活性成分，其中所述组分的组合表现出双峰或多峰释放曲线。 本发明还涉及含有这种多微粒改性释放组合物的固体口服剂型。

    Modified Release Famciclovir Compositions
    5.
    发明申请
    Modified Release Famciclovir Compositions 审中-公开
    改性释放泛昔洛韦组合物

    公开(公告)号：US20100136106A1

    公开(公告)日：2010-06-03

    申请号：US11568891

    申请日：2006-06-07

    申请人： Gary Liversidge ,  Scott Jenkins ,  John G. Devane ,  Paul Stark ,  Niall Fanning ,  Gurvinder Singh Rekhi

    发明人： Gary Liversidge ,  Scott Jenkins ,  John G. Devane ,  Paul Stark ,  Niall Fanning ,  Gurvinder Singh Rekhi

    IPC分类号： A61K31/52 ,  A61K9/48 ,  A61P31/22 ,  A61P31/20 ,  A61K9/58

    CPC分类号： A61K9/5078 ,  A61K9/5026 ,  A61K9/5084

    摘要： The invention relates to a multiparticulate modified release composition that, upon administration to a patient, delivers famciclovir in a bimodal, multimodal or continuous manner. The multiparticulate modified release composition comprises a first component and at least one subsequent component, the first component comprising a first population of active ingredient containing particles and the at least one subsequent component comprising a second population of active ingredient containing particles. The invention also relates to a solid oral dosage form containing such a multiparticulate modified release composition, and to a method for the treatment or suppression of viral infections.

    摘要翻译： 本发明涉及一种多微粒改性释放组合物，其在给予患者时以双峰，多峰或连续方式递送泛昔洛韦。 多微粒改性释放组合物包含第一组分和至少一个后续组分，第一组分包含含有颗粒的第一组活性成分和至少一种随后的组分，其包含第二组含有颗粒的活性成分。 本发明还涉及含有这种多微粒改性释放组合物的固体口服剂型，以及用于治疗或抑制病毒感染的方法。

    COMPOSITIONS COMPRISING NANOPARTICULATE NAPROXEN AND CONTROLLED RELEASE HYDROCODONE
    6.
    发明申请
    COMPOSITIONS COMPRISING NANOPARTICULATE NAPROXEN AND CONTROLLED RELEASE HYDROCODONE 审中-公开
    包含纳米颗粒纳普罗宁和受控释放氢化物的组合物

    公开(公告)号：US20080113025A1

    公开(公告)日：2008-05-15

    申请号：US11768154

    申请日：2007-06-25

    申请人： John G. Devane ,  Paul Stark ,  Niall Fanning ,  Gurvinder Singh Rekhi ,  Scott A. Jenkins ,  Gary Liversidge

    发明人： John G. Devane ,  Paul Stark ,  Niall Fanning ,  Gurvinder Singh Rekhi ,  Scott A. Jenkins ,  Gary Liversidge

    IPC分类号： A61K31/485 ,  A61K9/26

    CPC分类号： A61K31/485 ,  A61K9/145 ,  A61K9/146 ,  A61K9/5078 ,  A61K9/5084 ,  A61K45/06 ,  A61K2300/00

    摘要： The invention relates to a compositions comprising a nanoparticulate naproxen composition in combination with a multiparticulate modified release hydrocodone composition that, upon administration to a patient, delivers a hydrocodone in a bimodal or multimodal manner. The multiparticulate modified release composition comprises a first component and at least one subsequent component; the first component comprising a first population of hydrocodone-comprising particles and the at least one subsequent component comprising a second population of hydrocodone-comprising particles, wherein the combination of the components exhibit a bimodal or multimodal release profile. The invention also relates to a solid oral dosage form comprising such a combination composition.

    摘要翻译： 本发明涉及包含纳米颗粒萘普生组合物与多微粒改性释放氢可酮组合物组合的组合物，其在施用于患者时以双峰或多峰方式递送氢可酮。 多微粒改性组合物包含第一组分和至少一个后续组分; 所述第一组分包含第一群含氢可酮的颗粒，所述至少一个随后的组分包含第二组含有氢可酮的颗粒，其中所述组分的组合表现出双峰或多峰释放曲线。 本发明还涉及包含这种组合组合物的固体口服剂型。

    Modified Release Ticlopidine Compositions
    10.
    发明申请
    Modified Release Ticlopidine Compositions 审中-公开
    改良释放噻氯匹定组合物

    公开(公告)号：US20090297597A1

    公开(公告)日：2009-12-03

    申请号：US11569481

    申请日：2006-06-09

    申请人： Gary Liversidge ,  Scott Jenkins ,  Paul Stark ,  Niall M.N. Fanning ,  Gurvinder Singh Rekhi ,  John G. Devane

    发明人： Gary Liversidge ,  Scott Jenkins ,  Paul Stark ,  Niall M.N. Fanning ,  Gurvinder Singh Rekhi ,  John G. Devane

    IPC分类号： A61K9/48 ,  A61K9/00 ,  A61K9/14 ,  A61K31/4365 ,  A61K9/58 ,  A61K9/60 ,  A61P43/00

    CPC分类号： A61K9/5026 ,  A61K9/5047 ,  A61K9/5084 ,  A61K31/192 ,  A61K31/485

    摘要： The invention relates to a multiparticulate modified release composition that, upon administration to a patient, delivers ticlopidine in a bimodal, multimodal or continuous manner. The multiparticulate modified release composition comprises a first component and at least one subsequent component, the first component comprising a first population of active ingredient containing particles and the at least one subsequent component comprising a second population of active ingredient containing particles. The invention also relates to a solid oral dosage form containing such multiparticulate modified release composition, and to methods for inhibiting platelet aggregation, inhibiting blood clotting, and reducing risk of stroke in a patient.

    摘要翻译： 本发明涉及一种多微粒改性释放组合物，其在给予患者时以双峰，多峰或连续方式递送噻氯匹定。 多微粒改性释放组合物包含第一组分和至少一个后续组分，第一组分包含含有颗粒的第一组活性成分和至少一种随后的组分，其包含第二组含有颗粒的活性成分。 本发明还涉及含有这种多微粒释放组合物的固体口服剂型，以及用于抑制血小板聚集，抑制血液凝固和降低患者中风风险的方法。